Effects of benzo-a-pyrene on oxytocin-induced Ca2+ oscillations in myometrial cells
2006
Barhoumi R. | Awooda I. | Mouneimne Y. | Safe S. | Burghardt R.C. | Barhoumi, R., Depatrment of Veterinary Integrative Biosciences, Texas A and M University, College Station, TX 77843-4458, United States | Awooda, I., Depatrment of Veterinary Integrative Biosciences, Texas A and M University, College Station, TX 77843-4458, United States | Mouneimne, Y., Central Research Science Laboratory, American University of Beirut, Beirut, Lebanon | Safe, S., Department of Veterinary Physiology and Pharmacology, Texas A and M University, College Station, TX 77843-4466, United States | Burghardt, R.C., Depatrment of Veterinary Integrative Biosciences, Texas A and M University, College Station, TX 77843-4458, United States | Barhoumi, R.; Depatrment of Veterinary Integrative Biosciences, Texas A and M University, College Station, TX 77843-4458, United States; email: [email protected] | University: American University of Beirut; Faculty: Faculty of Agricultural and Food Sciences; Department: FAFS; | FAFS | [email protected] | Faculty of Agricultural and Food Sciences | Barhoumi, R | Awooda, I | Mouneimne, Y | Safe, S | Burghardt, RC | Barhoumi, R (reprint author), Texas AandM Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA. | American University of Beirut
Benzo-a-pyrene (BaP) is a polycyclic aromatic hydrocarbon that exists as a major environmental pollutant. The effect of this carcinogen-mutagen upon myometrial Ca2+ signaling in a human myometrial cell line (PHM1) was examined. Exposure of cells to BaP did not alter basal Ca2+ levels or the inositol(1,4,5) trisphosphate-releasable Ca2+ pool. However, BaP significantly decreased the initial oxytocin-induced Ca2+ transient and the frequency of oxytocin-induced Ca2+oscillations as well as delayed their onset. To determine the specific effects of BaP, pharmacologic agents that target intracellular Ca2+ homeostasis mechanisms were used. Genistein (a non-specific tyrosine kinase inhibitor) and AG1478 (an epidermal growth factor receptor blocker) markedly reduced the oxytocin-induced Ca2+ oscillations in control, but had no effect in BaP treated cells. Addition of epidermal growth factor or serum before or after oxytocin restored the Ca2+ oscillations in BaP treated cells to a level similar to control cells, while the K+ channel blocker tetraethylammonium chloride, partially restored the Ca2+ response. These data suggest that the tyrosine kinase pathway, which is part of the G-protein coupled receptor pathway response to oxytocin in PHM1 cells, is a target of BaP action and that EGF or serum can restore the oxytocin-induced Ca2+ oscillations. © 2006 Elsevier Ireland Ltd. All rights reserved.
Afficher plus [+] Moins [-]Barhoumi R, 2002, TOXICOL SCI, V68, P444, DOI 10.1093-toxsci-68.2.444; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038-nrm1155; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074-jbc.M011571200; Burghardt RC, 1999, BIOL REPROD, V60, P777, DOI 10.1095-biolreprod60.4.777; DAVILA DR, 1995, J TOXICOL ENV HEALTH, V45, P101; Dolmetsch RE, 1998, NATURE, V392, P933; Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054-ceca.1999.0095; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016-0006-291X(90)91544-3; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074-jbc.M311981200; Kawanabe Y, 2004, J NEUROSURG, V100, P1066, DOI 10.3171-jns.2004.100.6.1066; LAMMINEN S, 1993, TOXICOLOGY, V83, P41, DOI 10.1016-0300-483X(93)90090-F; Lederer WJ, 2000, AM J PHYSIOL-CELL PH, V278, P235; LEGRAVEREND C, 1984, TERATOLOGY, V29, P35, DOI 10.1002-tera.1420290106; Loch-Caruso R, 2002, INT J HYG ENVIR HEAL, V205, P121, DOI 10.1078-1438-4639-00137; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACKENZIE KM, 1981, BIOL REPROD, V24, P183, DOI 10.1095-biolreprod24.1.183; MacLeod RJ, 2004, BIOCHEM BIOPH RES CO, V320, P455, DOI 10.1016-j.bbrc.2004.05.198; McGarry MA, 2002, BIOCHEM BIOPH RES CO, V294, P101, DOI 10.1016-S0006-291X(02)00437-0; Monga M, 1996, BIOL REPROD, V55, P427, DOI 10.1095-biolreprod55.2.427; Morrison JJ, 1996, HUM REPROD, V11, P2285; Mounho BJ, 1998, TOXICOL APPL PHARM, V149, P80, DOI 10.1006-taap.1997.8345; Palmier B, 1999, J PHARMACOL EXP THER, V289, P1022; Parekh AB, 1997, PHYSIOL REV, V77, P901; Robb-Gaspers LD, 1998, BBA-BIOENERGETICS, V1366, P17, DOI 10.1016-S0005-2728(98)00118-2; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109-10408449709021615; Salas VM, 1998, TOXICOL APPL PHARM, V151, P367, DOI 10.1006-taap.1998.8455; Sharovskaja JJ, 2004, BIOCHEMISTRY-MOSCOW+, V69, P413, DOI 10.1023-B:BIRY.0000026197.00159.0a; SMIRNOV SV, 1992, J PHYSIOL-LONDON, V457, P431; Tai CJ, 2001, J CLIN ENDOCR METAB, V86, P773, DOI 10.1210-jc.86.2.773; Tannheimer SL, 1999, MOL CARCINOGEN, V25, P48, DOI 10.1002-(SICI)1098-2744(199905)25:148
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par American University of Beirut
Découvrez la collection de ce fournisseur de données dans AGRIS